RG
BLRX

Rathbones Group’s BioLineRX BLRX Stock Holding History

Rathbones Group’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-792
Closed -$6.78K – 609
2024
Q4 		$6.78K Sell
792
-204
-20% -$3.01K ﹤0.01% 606
2024
Q3 		$21.3K Hold
996
– – ﹤0.01% 597
2024
Q2 		$22.7K Hold
996
– – ﹤0.01% 606
2024
Q1 		$44.6K Hold
996
– – ﹤0.01% 594
2023
Q4 		$62.5K Hold
996
– – ﹤0.01% 579
2023
Q3 		$72.5K Buy
+996
New +$66.9K ﹤0.01% 584

Other funds holding BLRX

Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Rathbones Group's BLRX Position: Q1 2025 in Review

Rathbones Group sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 792 shares — an estimated $6.78K sold.

Rathbones Group first reported a position in BLRX in Q3 2023 and held it in 6 quarters. The position peaked at $72.5K in Q3 2023. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

  • Rathbones Group reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
  • Rathbones Group sold 792 BioLineRX shares in Q1 2025, an estimated $6.78K.
  • Rathbones Group first reported a position in BioLineRX in Q3 2023 and held it in 6 quarters.
  • Rathbones Group's BioLineRX position peaked at $72.5K in Q3 2023.
  • 12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on Rathbones Group's 13F filing for Q1 2025, filed 13 May 2025.